“…The A 2A R overactivation associated with brain dysfunction and disease is not only sustained by an increased bioavailability of the trigger of A 2A R-ATP-derived extracellular adenosine-but also involves an up-regulation of A 2A R in the afflicted brain areas (reviewed in Cunha, 2016). Indeed, an increased density of cortical A 2A R has been reported in animal models of epilepsy (Rebola et al, 2005;Cognato et al, 2010;Canas et al, 2018;Crespo et al, 2018), Rasmussen's encephalopathy (He et al, 2020), TBI (Zhao et al, 2017), AD (Espinosa et al, 2013;Viana da Silva et al, 2016;Silva et al, 2018), Lyme neuroborreliosis (Smith et al, 2014), ALS (Seven et al, 2020), or chronic stress/depression (Kaster et al, 2015;Machado et al, 2017), as well as in the diseased human brain (Albasanz et al, 2008;Temido-Ferreira et al, 2020). Likewise, A 2A R levels are also increased in the cerebellum of Machado-Joseph's ataxic mice (Gonçalves et al, 2013) and in the amygdala or fear-conditioned mice (Simões et al, 2016).…”